Kyowa Kirin Co., Ltd.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2021, 2017, 2012, 2011, 2009-04 to 2009-12 (Japan), 2009-01 to 2009-12 (Overseas), 2002-04 to 2003-03

In its 2023 reporting, Kyowa Kirin Co., Ltd. disclosed greenhouse gas emissions of 1.7K tCO2e (2023). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
1.7K tCO2e (2023)
2023
⚡
Renewable Energy
83% (2023)
of total energy
💧
Water Usage
1.7M m3 (2023)
2023
⚙️
Energy Use
78.0M kWh (2023)
2023

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20231.7K tCO2e (2023)
2017366 thousand tons
2012246.6K tons/year (CO2)
2011240.0K tCO2e/year (2011)
2009-04 to 2009-12 (Japan), 2009-01 to 2009-12 (Overseas)643.0K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce CO2 emissions by 51% compared with 2019 (FY2024)
  • 100% renewable energy at major Japan business locations by 2025

📅 Medium-term

  • Reduce CO2 emissions by 55% from 2019 levels by 2030
  • Fully convert power consumed by the Group to renewable energy by 2040
  • Reduce water withdrawal by 40% from 2019 levels by 2030

🔭 Long-term

  • Net zero greenhouse gas emissions in its entire value chain by 2050

🌱 ESG Focus Areas

Climate ChangeWater Resource ManagementHuman RightsCorporate GovernanceSupply Chain Management

⚠️ Challenges & Risks +

  • Global trend toward stricter healthcare policies and regulations to reduce medical costs
  • Growing needs for the practical application of new modalities that can cure or control disease progression
  • Depletion of monoclonal antibody and small molecule drug targets
  • Shift in the pharmaceutical industry to strategies targeting narrow treatment areas
  • Reductions to drug prices and tighter criteria for treatment reimbursements

📋 Report Information

Reporting Period: 2023
Frameworks: International Integrated Reporting Framework, Guidance for Collaborative Value Creation 2.0